Kamada (KMDA) Acquisitions (2021)
Kamada's (KMDA) quarterly Acquisitions came in at -$95.0 million in Q4 2021, down 6666.31% quarter-over-quarter from -$1.4 million in Q1 2021.
Powered by 
Analysis
Kamada (KMDA) Acquisitions (2021) Analysis & Trends
Kamada (KMDA) has reported Acquisitions for 1 consecutive years, with -$95.0 million the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Acquisitions changed N/A year-over-year to -$95.0 million; the trailing twelve-month figure through Dec 2021 stood at -$96.4 million (changed N/A YoY), and the FY2021 full-year result was -$96.4 million, changed N/A from the prior year.
- Acquisitions slipped to -$95.0 million in Q4 2021 per KMDA's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Acquisitions topped out at -$1.4 million in Q1 2021 and bottomed at -$95.0 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.21 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | - |